Corvus Pharmaceuticals

CRVS Rare disease Lead: Phase 3 ★ Read the deep dive → 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-12

Catalyst timeline

Soquelitinib AD Ph3 interimLate 2026Soquelitinib AD Ph3 interim, Late 2026, notable
Soquelitinib ALPS Ph3 interimLate 2026Soquelitinib ALPS Ph3 interim, Late 2026, notable
Soquelitinib PTCL Ph3 interimLate 2026Soquelitinib PTCL Ph3 interim, Late 2026, notable
Soquelitinib Atopic Dermatitis Ph2 topline3Q 2027Soquelitinib Atopic Dermatitis Ph2 topline, 3Q 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

soquelitinib

CPI-818

Small Molecule Target: ITK

Peripheral T Cell Lymphoma Phase 3 oral NCT03952078
Atopic Dermatitis Phase 2 oral NCT06345404
Autoimmune Lymphoproliferative Syndrome Phase 2 oral NIAID
Hidradenitis Suppurativa Phase 1 oral NCT07828860

ciforadenant

Small Molecule Target: A2A receptor

Renal Cell Carcinoma Phase 2 Phase 1b/2 trial oral Kidney Cancer Research Consortium NCT02655822

mupadolimab

CPI-006

Protein Target: CD73

Undisclosed indication NCT04464395

Biotech Distilled coverage (1)

2026-05-19 Corvus Pharmaceuticals (CRVS) - Scientific Deep Dive for Soquelitinib and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.